<DOC>
	<DOC>NCT00784888</DOC>
	<brief_summary>The purpose of this study is to follow safety and quality of life outcomes on patients switching from tamoxifen therapy to aromatase inhibitor therapy.</brief_summary>
	<brief_title>Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor Therapy</brief_title>
	<detailed_description>Group of patients using the same aromatase inhibitor</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Patients with endocrine responsive early stage postmenopausal breast cancer. Patients who received tamoxifen for 23 years as adjuvant endocrine therapy. Patients who were approved to switch to aromatase inhibitor treatment during the patient recruitment period. Patients who were informed about the study and accepted to participate. Patients having a psychological disorder which will prevent their understanding of questionnaires used for evaluation of quality of life and / or patients who are illiterate.</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>aromatase inhibitor</keyword>
	<keyword>quality of life</keyword>
	<keyword>safety</keyword>
	<keyword>postmenopausal breast cancer</keyword>
</DOC>